Legend Biotech (LEGN) shares jumped roughly 40% on Tuesday after early Phase 1 data for its in vivo CAR-T candidate LB2501 showed all six patients in the higher-dose cohort responded – five completely – raising the prospect of a lower-cost, off-the-shelf alternative to today’s labour-intensive cell therapies.
For long-horizon investors, the read-through extends well beyond a single data point: if in vivo CAR-T manufacturing proves viable at scale, it could dramatically reduce Legend’s cost of goods and broaden the addressable patient population for what is already a high-growth franchise anchored by Carvykti (cilta-cel) in multiple myeloma. 1
Key Takeaways
- All six higher-dose patients responded; five achieved complete response.
- No dose-limiting toxicities or serious adverse events were reported.
- LB2501 eliminates ex vivo manufacturing, potentially cutting costs sharply.
Market Reaction & Context
LEGN closed up approximately 40% on Tuesday – one of the sharpest single-day moves in the Nasdaq biotech sector this year – well ahead of the broader XBI biotech ETF, which was little changed on the session. 2 The stock’s analyst consensus target had stood at $55.39 before the announcement, against a prior close of $25.51, implying the market had already priced in significant scepticism about the pipeline beyond Carvykti. 3
The in vivo CAR-T space is attracting boardroom attention across the industry: AstraZeneca and Eli Lilly have both struck deals in this field in recent months, signalling that large-cap pharma views the technology as a credible threat to conventional ex vivo approaches. 1
What the Data Actually Show
As of April 1, twelve patients with relapsed or refractory B-cell non-Hodgkin lymphoma had been enrolled in two dose cohorts. 1 In the higher-dose group of six patients, preliminary data showed a 100% overall response rate and an 83% complete response rate – results that would be competitive with approved ex vivo CAR-T products in this indication.
Unlike traditional CAR-T therapies, which require extracting a patient’s T cells, engineering them outside the body and reinfusing them in a process that can take three to five weeks, LB2501 delivers the CAR-T programming directly via a single intravenous infusion. 2 CAR-T cells generated through this method were detectable in peripheral blood for up to 116 days, suggesting meaningful in vivo persistence without external manufacturing. 1
The safety profile was notably clean: no dose-limiting toxicities, no serious adverse events and no fatalities were reported. Infusion-related reactions occurred in nine of twelve patients but resolved within a two-day median. 1 For a patient population that is typically heavily pre-treated and fragile, that tolerability profile is commercially relevant.
Legend did not disclose granular data from the lower-dose cohort and said full results would be presented at a medical conference later in June. 1
Pipeline Durability & Margin Implications
Carvykti generated roughly $597 million in sales for partner Johnson & Johnson in Q1 2026, while Legend reported Q1 revenue of $305.1 million against a consensus estimate of $306.5 million – a near-miss that had weighed on the shares before Tuesday’s catalyst. 3 Positive LB2501 data reframes the investment thesis: rather than a single-product story facing eventual myeloma market saturation, Legend now has evidence of a platform technology with potential application across multiple B-cell malignancies.
The cost structure argument is equally significant. Standard autologous CAR-T manufacturing has been estimated to carry total treatment costs as high as $500,000 per patient. 4 Eliminating the ex vivo engineering step could reduce that burden substantially, opening markets in health systems where reimbursement for current-generation therapies remains constrained.
Management View & Outlook
“By generating CAR-T cells directly within the patient, this approach has the potential to simplify treatment delivery and expand access for patients who may not be able to receive traditional CAR-T cell therapies,” Chief Executive Ying Huang said. 1
Legend said LB2501 could represent a “scalable, readily accessible” immunotherapy for B-cell malignancies, though the company acknowledged that longer follow-up is needed before drawing firm efficacy conclusions. 1 Full data at the June medical meeting will be closely watched for durability of response and any late-emerging toxicity signals.
Risks to the Thesis
The trial enrolled only twelve patients, making statistical inference premature. The technology must still demonstrate sustained remissions over 12 to 24 months to compete with the durability track records of established ex vivo products such as Kite’s Yescarta or Bristol Myers Squibb’s Breyanzi. Regulatory pathways for in vivo CAR-T are also uncharted, adding approval timeline uncertainty that long-horizon investors should factor into their models.
Not investment advice. For informational purposes only.
References
1Roy, Sriparna (2026-06-02). “Legend’s experimental cell therapy shows promise in blood cancer patients”. Reuters via Yahoo News. Retrieved 2026-06-02.
2(2026-06-02). “Legend’s experimental cell therapy shows promise in blood cancer patients”. Reuters via TradingView. Retrieved 2026-06-02.
3(2026-06-02). “Legend’s experimental cell therapy shows promise in blood cancer patients”. Reuters via MarketScreener. Retrieved 2026-06-02.
4Han, Bhavani; et al. (2023). “From bench to bedside: the history and progress of CAR T cell therapy”. Frontiers in Immunology via PubMed Central. Retrieved 2026-06-02.